A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2015
At a glance
- Drugs XP 23829 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors XenoPort
- 16 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Sep 2015 Results published in XenoPort media release.
- 15 Sep 2015 Primary endpoint (The percent change in PASI (Psoriasis Area and Severity Index) score from Baseline) has been met.